Reflections on the Future of Pharmaceutical Public-Private Partnerships: From Input to Impact

被引:33
|
作者
de Vrueh, Remco L. A. [1 ]
Crommelin, Daan J. A. [2 ]
机构
[1] Lygature, Utrecht, Netherlands
[2] UIPS Utrecht Univ, Utrecht Inst Pharmaceut Sci, Dept Pharmaceut, Utrecht, Netherlands
关键词
key drivers; performance evaluation; public-private-partnerships; R&D business models; UNIVERSITY-INDUSTRY ALLIANCES; CONFLICTS-OF-INTEREST; ALZHEIMERS-DISEASE; DRUG DEVELOPMENT; OPEN INNOVATION; HEALTH PARTNERSHIPS; BIG PHARMAS; MEDICINES; LESSONS; SCIENCE;
D O I
10.1007/s11095-017-2192-5
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Public Private Partnerships (PPPs) are multiple stakeholder partnerships designed to improve research efficacy. We focus on PPPs in the biomedical/pharmaceutical field, which emerged as a logical result of the open innovation model. Originally, a typical PPP was based on an academic and an industrial pillar, with governmental or other third party funding as an incentive. Over time, other players joined in, often health foundations, patient organizations, and regulatory scientists. This review discusses reasons for initiating a PPP, focusing on precompetitive research. It looks at typical expectations and challenges when starting such an endeavor, the characteristics of PPPs, and approaches to assessing the success of the concept. Finally, four case studies are presented, of PPPs differing in size, geographical spread, and research focus.
引用
收藏
页码:1985 / 1999
页数:15
相关论文
共 50 条